Search Results - therapeuticarea+%3e+respiratory

6 Results Sort By:
Optimizing RSV Infection Monitoring and High-Throughput Screening Through GFP Expression in the First-Gene Position of Respiratory Syncytial Virus (RSV) Strain A2
In this technology, researchers have engineered a modified version of Respiratory Syncytial Virus (RSV) strain A2 using reverse genetics to incorporate green fluorescent protein (GFP) into the first-gene position. This genetic modification allows for the efficient monitoring of RSV infection and the screening of potential chemical inhibitors. The GFP...
Published: 12/10/2024   |   Inventor(s): Peter Collins, Ursula Buchholz, Cindy Luongo
Keywords(s):  
Category(s): Application > Diagnostics, Application > Research Materials, Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Computational models/software, ResearchProducts > Research Equipment, TherapeuticArea > Infectious Disease, TherapeuticArea > Respiratory
Enhanced GFP-Expressing Human Metapneumovirus (HMPV): A Versatile Tool for Virology Research and Antiviral Drug Screening
The technology involves genetically engineering Human Metapneumovirus (HMPV) to express enhanced green fluorescent protein (GFP), enabling the monitoring of virus infection and gene expression through GFP fluorescence. This system serves as a sensitive and versatile tool for virology research, antiviral drug screening, and diagnostic applications. Researchers...
Published: 12/10/2024   |   Inventor(s): Peter Collins, Ursula Buchholz, Stephanie Biacchesi
Keywords(s):  
Category(s): Application > Diagnostics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Plasmids/Vectors, ResearchProducts > Research Equipment, TherapeuticArea > Respiratory, TherapeuticArea > Infectious Disease
Development of a High-Throughput Screening Tool for RSV Inhibition Using Engineered RSV Expressing GFP and Luciferase Genes
The technology involves the genetic engineering of Respiratory Syncytial Virus (RSV) to express two additional genes, green fluorescent protein (GFP) and Renilla luciferase, from different positions within the viral genome. GFP serves as a visual marker for RSV infection, allowing researchers to monitor and track infected cells using fluorescence microscopy,...
Published: 12/10/2024   |   Inventor(s): Peter Collins, Mark Peeples
Keywords(s):  
Category(s): Application > Diagnostics, Application > Research Materials, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, ResearchProducts > Research Equipment, TherapeuticArea > Infectious Disease, TherapeuticArea > Respiratory
Single Source-Detector Separation Approach to Calculate Tissue Oxygen Saturation
Summary: The National Institute of Child Health and Human Development (NICHD) seeks partners and/or licensees to further develop and commercialize the miniaturized tissue oximeter for implementing the single source-detector separation algorithm in existing devices/systems to collect tissue oxygen saturation. Description of Technology: Tissue oxygen...
Published: 12/20/2024   |   Inventor(s): Thien Nguyen, Amir Gandjbakhche, Soongho Park, Brian Hill
Keywords(s):  
Category(s): Application > Medical Devices, TherapeuticArea > Respiratory, TherapeuticArea > Neurology, TherapeuticArea > Infectious Disease, Collaboration Sought > Collaboration, Collaboration Sought > Licensing
High Density Lipoprotein Targeting Protease Inhibitor Peptide for the Treatment of Alpha-1-antitrypsin (A1AT) Deficiency
This technology includes a novel concept and design for a lipoprotein targeting protease inhibitor for the treatment of Alpha-1-antitrypsin (A1AT) deficiency. A1AT deficiency occurs in about 1 in 2500 individuals in the United States and Europe, and people with this condition develop severe liver disease and emphysema/chronic obstructive pulmonary disease...
Published: 12/13/2024   |   Inventor(s): Alan Remaley, Scott Gordon
Keywords(s):  
Category(s): Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Respiratory
Cycioxygenase-2 Inhibition for the Treatment-SAA-high Asthma
This technology includes the use of cyclooxygenase-2 (COX-2) inhibitors for the treatment of serum amyloid A (SAA)-high asthma. A commercially available enzyme-linked immunosorbent assay was used to analyze serum levels of SAA in a cohort of 154 non-asthmatic subjects to establish the upper 95th centile value of serum SAA in healthy individuals as >...
Published: 9/11/2024   |   Inventor(s): Stewart Levine, Xianglan Yao, Alan Remaley, Amisha Barochia, Maryann Kaler
Keywords(s):  
Category(s): Application > Diagnostics, Application > Therapeutics, Collaboration Sought > Licensing, TherapeuticArea > Immunology, TherapeuticArea > Respiratory